anlotinib
Small moleculeexperimental
Clinical trial activity
409 trials · 127 clinical orgs · 0 marketing orgs
Phase 1
67
Phase 2
322
Phase 3
41
Phase 4
18
Earliest trial started May 1, 2011 (NCT01833923)
Timeline
Indications
Approved for
Studied for
- Ablation Techniques · Phase 3
- Adenocarcinoma · Phase 2
- Adenocarcinoma of Lung · Phase 1/Phase 2
- Adnexal Diseases · Phase 2
- Adolescent · Phase 2
- Angiogenesis Inhibitors · Phase 2
- Angiogenesis Modulating Agents · Phase 3
- Antineoplastic Agents · Phase 2
- Bile Duct Neoplasms · Phase 2
- Biliary Tract Neoplasms · Phase 3
- Brachiocephalic Trunk · Phase 2
- Brain Neoplasms · Phase 2
- BRCA1 Protein · Phase 2
- Breast Neoplasms · Phase 2
- Carboplatin · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 4
- Carcinoma, Ovarian Epithelial · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Small Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Catheters · Phase 3
- Chemoradiotherapy · Phase 1
- Child · Phase 2
- Cholangiocarcinoma · Phase 2
- Chondrosarcoma · Phase 2
- Chordoma · Phase 2
- Cisplatin · Phase 2
- Colonic Diseases · Phase 2
- Colorectal Neoplasms · Phase 3
- Craniopharyngioma · Phase 1/Phase 2
- Digestive System Diseases · Phase 2
- Digestive System Neoplasms · Phase 2
- Docetaxel · Phase 2
- Doxorubicin · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Drug Resistance · Phase 3
- Drugs, Investigational · Phase 3
- Drug Therapy · Phase 3
- Drug Therapy, Combination · Phase 2
- Endocrine System Diseases · Phase 2
- Endometrial Neoplasms · Phase 3
- Esophageal Diseases · Phase 2
- Esophageal Neoplasms · Phase 3
- Esophageal Squamous Cell Carcinoma · Phase 2/Phase 3
- Esophagogastric Junction · Phase 2
- Essential Tremor · Phase 2
- Extremities · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Gallbladder Neoplasms · Phase 2
- Gastrointestinal Diseases · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- Gastrointestinal Stromal Tumors · Phase 2
- Genes, erbB-1 · Phase 3
- Genital Diseases, Female · Phase 2
- Genital Neoplasms, Female · Phase 2
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Graft vs Host Disease · Phase 2
- Hamartoma · Phase 4
- Head and Neck Neoplasms · Phase 4
- Immune Checkpoint Inhibitors · Phase 1/Phase 2
- Immunotherapy · Phase 2
- Intestinal Diseases · Phase 2
- Intestinal Neoplasms · Phase 2
- Kidney Neoplasms · Phase 2
- Leiomyosarcoma · Phase 3
- Liver Diseases · Phase 1
- Liver Neoplasms · Phase 2
- Lung Diseases, Interstitial · Phase 2/Phase 3
- Lung Neoplasms · Phase 3
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, T-Cell · Phase 2
- Maintenance · Phase 3
- Melanoma · Phase 2
- Mesothelioma · Phase 2
- Mesothelioma, Malignant · Phase 2
- Molecular Targeted Therapy · Phase 2
- Mouth Neoplasms · Phase 2
- Multiple Myeloma · Phase 1
- Mutation · Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Nasopharyngeal Neoplasms · Phase 2
- Neoadjuvant Therapy · Phase 2/Phase 3
- Neoplasm Metastasis · Phase 2
- Neoplasm, Residual · Phase 2
- Neoplasms · Phase 3
- Neoplasms by Histologic Type · Phase 2
- Neoplasms by Site · Phase 2
- Neoplasms, Glandular and Epithelial · Phase 2
- Neoplasms, Squamous Cell · Phase 2
- Neuroblastoma · Phase 2
- Osteosarcoma · Phase 1
- Ovarian Diseases · Phase 2
- Ovarian Neoplasms · Phase 4
- Pancreatic Neoplasms · Phase 3
- Paraganglioma · Phase 2
- Paraganglioma, Extra-Adrenal · Phase 2
- Pemetrexed · Phase 2
- Pharmacokinetics · Phase 2
- Pharmacological and Toxicological Phenomena · Phase 2
- Pheochromocytoma · Phase 2
- Poly(ADP-ribose) Polymerase Inhibitors · Phase 2
- Precision Medicine · Phase 2
- Progression-Free Survival · Phase 2
- Proto-Oncogene Proteins B-raf · Phase 2
- Quality of Life · Phase 2
- Radiation Oncology · Phase 2
- Radiotherapy · Phase 4
- Radiotherapy, Intensity-Modulated · Phase 2
- Rectal Diseases · Phase 2
- Rectal Neoplasms · Phase 2
- Rhabdomyosarcoma · Phase 2
- Safety · Phase 2
- Sarcoma · Phase 4
- Sarcoma, Alveolar Soft Part · Phase 3
- Sarcoma, Ewing · Phase 2
- Sarcoma, Synovial · Phase 3
- Small Cell Lung Carcinoma · Phase 4
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2/Phase 3
- Survival · Phase 2
- Thymoma · Phase 2
- Thyroid Neoplasms · Phase 4
- Triple Negative Breast Neoplasms · Phase 3
- Tumor Suppressor Protein p53 · Phase 2
- Urogenital Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Wounds and Injuries · Phase 2
Mechanism of action
PDGFRB inhibitor
Multi-targeted receptor tyrosine kinase inhibitor
FLT4 inhibitor
Multi-targeted receptor tyrosine kinase inhibitor
KDR inhibitor
Multi-targeted receptor tyrosine kinase inhibitor
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
Multi-targeted receptor tyrosine kinase inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545021 ↗
Also known as
- al3818
- al3818
- al 3818
- al 3818
- al-3818
- al-3818
- anlotinib
- anlotinib
- anlotinib
- anlotinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07307443 | Phase 2 | Feb 1, 2026 | Chinese Academy of Medical Sciences, Hebei University, Peking University |
| NCT07294261 | Phase 2 | Dec 23, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Sun Yat-Sen University |
| NCT07165951 | Phase 3 | Nov 30, 2025 | Government of China |
| NCT07172412 | Phase 2 | Nov 30, 2025 | Tianjin Medical University |
| NCT07286240 | Phase 2 | Nov 15, 2025 | Guangzhou Medical University |
| NCT07205185 | Phase 2 | Oct 1, 2025 | Fudan University |
| NCT07156643 | Phase 2 | Oct 1, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Nanjing Medical University |
| NCT07137884 | Phase 2 | Oct 1, 2025 | Sun Yat-Sen University |
| NCT07193186 | Phase 2 | Oct 1, 2025 | Fudan University |
| NCT07128693 | Phase 2 | Sep 30, 2025 | Zhengzhou University |
| NCT07075250 | Phase 4 | Sep 1, 2025 | Capital Medical University, Jiao Tong University, Peking University, Shanxi Medical University, Tianjin Medical University, Zhengzhou University |
| NCT07139470 | Phase 1/Phase 2 (Phase 2) | Aug 15, 2025 | Tianjin Medical University |
| NCT07022301 | Phase 2 | Jul 31, 2025 | Wannan Medical College |
| NCT06977828 | Phase 2 | Jul 20, 2025 | Nanjing Medical University |
| NCT07010393 | Phase 4 | Jul 1, 2025 | Fujian Medical University |
| NCT06848439 | Phase 2 | Jun 15, 2025 | Jiangsu Cancer Institute & Hospital |
| NCT07025174 | Phase 2 | Jun 1, 2025 | Zhejiang University |
| NCT06978153 | Phase 2 | May 20, 2025 | People's Liberation Army of China |
| NCT06874933 | Phase 2 | May 4, 2025 | Zhejiang University |
| NCT06951841 | Phase 4 | Apr 30, 2025 | China Medical University |
Showing 20 of 409 trials
Page 1 / 21
Organizations
Research & Development (127)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 122 | 70 | 5 | 2011 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 55 | 44 | 5 | 2011 |
| Jiao Tong University | Academic/Hospital | 35 | 25 | 5 | 2013 |
| Sun Yat-Sen University | Academic/Hospital | 27 | 23 | 4 | 2018 |
| Fudan University | Academic/Hospital | 25 | 21 | 4 | 2018 |
| Nanjing Medical University | Academic/Hospital | 22 | 18 | 3 | 2011 |
| Tianjin Medical University | Academic/Hospital | 20 | 13 | 4 | 2013 |
| People's Liberation Army of China | Government | 18 | 12 | 4 | 2018 |
| Central South University | Academic/Hospital | 15 | 12 | 4 | 2018 |
| Henan Medical University | Academic/Hospital | 15 | 13 | 5 | 2019 |
| Peking University | Academic/Hospital | 14 | 12 | 2 | 2018 |
| Zhejiang University | Academic/Hospital | 14 | 12 | 2 | 2018 |
| Zhengzhou University | Academic/Hospital | 13 | 11 | 3 | 2018 |
| Shandong University | Academic/Hospital | 9 | 9 | 2 | 2018 |
| Fujian Medical University | Academic/Hospital | 7 | 4 | 3 | 2018 |
| Sichuan University | Academic/Hospital | 7 | 5 | 2 | 2018 |
| Xijing Hospital | Academic/Hospital | 7 | 6 | 2 | 2019 |
| Akeso Pharmaceuticals, Inc. | For profit | 6 | 3 | 1 | 2018 |
| Jilin University | Academic/Hospital | 6 | 3 | 2 | 2019 |
| Advenchen Laboratories, LLC | For profit | 5 | 4 | 3 | 2015 |
127 organizations
Page 1 / 7